TRIAL DETAIL

A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Drug:
Trial Name:
A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Terminated
Phase:
2
Start Date 08/01/2011
Age of Trial (yrs) 10.4
Treatment Phase:
Gleevec-resistant
Drug Category:
PDGFRa inhibitor
Strategy:
Block PDGFRA
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
14244, CP15-1008, 15B-IE-JGDH, 2010-022560-12
Sponsor:
ImClone LLC
Patient Contact:
ImClone: ClinicalTrials@Imclone.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
The purpose of this study is to evaluate the tumor response of stable disease (SD) or better at 12 weeks in patients with Gastrointestinal Stromal Tumors (GIST) harboring PDGFRα mutations and patients with GIST not harboring PDGFRα mutations.

Trial Links

 

Trial Results

 

Drug Information

Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.
 
Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFRα in patients with advanced solid malignancies.
 
NCI Dictionary - IMC-3G3
 

Trial Sites

Name
Address
City
State
Zip
Country
Baltimore
MD
21215
USA
450 Brookline Ave
Boston
MA
02215-5450
USA
Mannheim
68167
Germany
Tuebingen
D-72076
Germany
Leiden
2333
Netherlands
Warsaw
02-781
Poland
Madrid
28050
Spain
Los Angeles
CA
90095
USA
Post Falls
ID
83854
USA
Minneapolis
MN
55455
USA
3181 S.W. Sam Jackson Park Rd.
Portland
OR
97239
USA
Leuven
B-3000
Belgium
Edegem
B-2650
Belgium
Berlin
Germany
Milan
20132
Italy
Madrid
28041
Spain
Chicago
IL
USA
Chicago
IL
USA
Essen
Germany